Patents Assigned to Greenovation Biotech GmbH
-
Publication number: 20200277347Abstract: The invention relates to a polypeptide comprising a C3 convertase effector domain, a C5 convertase effector domain and optionally a terminal complex inhibitory effector domain which is resistant to deregulation by physiologic FHR-Proteins and has a dimerization motif, and to its therapeutic use.Type: ApplicationFiled: March 20, 2020Publication date: September 3, 2020Applicant: GREENOVATION BIOTECH GMBHInventors: Stefan MICHELFELDER, Karsten HÄFFNER
-
Patent number: 10640540Abstract: The invention relates to a polypeptide comprising a C3 convertase effector domain, a C5 convertase effector domain and optionally a terminal complex inhibitory effector domain which is resistant to deregulation by physiologic FHR-Proteins and has a dimerization motif, and to its therapeutic use.Type: GrantFiled: December 23, 2016Date of Patent: May 5, 2020Assignee: GREENOVATION BIOTECH GMBHInventors: Stefan Michelfelder, Karsten Häffner
-
Publication number: 20190300589Abstract: The invention relates to a polypeptide comprising a C3 convertase effector domain, a C5 convertase effector domain and optionally a terminal complex inhibitory effector domain which is resistant to deregulation by physiologic FHR-Proteins and has a dimerization motif, and to its therapeutic use.Type: ApplicationFiled: December 23, 2016Publication date: October 3, 2019Applicant: GREENOVATION BIOTECH GMBHInventors: Stefan MICHELFELDER, Karsten HÄFFNER
-
Patent number: 10253098Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.Type: GrantFiled: May 28, 2015Date of Patent: April 9, 2019Assignee: GREENOVATION BIOTECH GMBHInventors: Manfred Schuster, Ralf Kircheis, Andreas Nechansky, Wolfgang Jost, Gilbert Gorr
-
Patent number: 10081789Abstract: The invention relates to a method for separating off a liquid supernatant from cells, comprising the steps: providing a mixture of the cells with a liquid, charging a first filter housing with the mixture, wherein in the filter housing a filter having a pore size of between 4 ?m and 50 ?m is provided on a flat base surface pierced in a sieve manner and the walls of the filter housing are connected so as to seal with the flat base surface that is pierced in a sieve manner, applying a differential pressure of at least 0.5 bar on the mixture, as a result of which the liquid portion of the mixture is forced through the filter and a filter cake containing cells remains in the filter housing, and removal of the filtered liquid.Type: GrantFiled: July 19, 2013Date of Patent: September 25, 2018Assignee: GREENOVATION BIOTECH GMBHInventors: Grosse Thomas, Niederkrüger Holger, Schaaf Andreas
-
Publication number: 20180016648Abstract: The present invention relates to a lysosomal protein composition comprising a plurality of lysosomal proteins that are potentially diversely glycosylated according to a glycosylation pattern, wherein said glycosylation pattern has at least 45% paucimannosidic N-glycans; a method of manufacturing the lysosomal protein composition in a bryophyte plant or cell, and medical and non-medical uses of the lysosomal protein composition. E.g. the lysosomal protein can be a-Galactosidase for the treatment of Fabry Disease or ?-Glucoceramidase for the treatment of Gaucher's Disease. The unique glycosylation results in improved therapeutic efficacy—surprisingly even without mannose-6-phosphate that is common for CHO cell produced lysosomal proteins.Type: ApplicationFiled: March 17, 2016Publication date: January 18, 2018Applicant: GREENOVATION BIOTECH GMBHInventors: Paulina DABROWSKA-SCHLEPP, Fode BENJAMIN, Andreas BUSCH, Holger NIEDERKRÜGER, Andreas SCHAAF
-
Patent number: 9850513Abstract: The invention relates to a method for producing a recombinant protein in cells with a cell wall, comprising the step of increasing the secretion of the recombinant protein through the cell wall by expression of the protein in the cells in a culture medium containing a combination of a surface-active polymer and monovalent metal ions and with an osmolarity at least 0.32 osmol/L, said invention further relating to culture media and nutrient mixtures for the method.Type: GrantFiled: April 17, 2013Date of Patent: December 26, 2017Assignee: GREENOVATION BIOTECH GMBHInventors: Wolfgang Jost, Mathias Knappenberger, Doreen Claussnitzer, Andreas Schaaf
-
Publication number: 20160000914Abstract: The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations.Type: ApplicationFiled: September 15, 2015Publication date: January 7, 2016Applicants: GREENOVATION BIOTECH GMBH, MERIDIAN BIOPHARMACEUTICALS GMBHInventors: Hans LOIBNER, Gottfried HIMMLER
-
Publication number: 20150284461Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.Type: ApplicationFiled: May 28, 2015Publication date: October 8, 2015Applicant: GREENOVATION BIOTECH GMBHInventors: Manfred Schuster, Ralf Kircheis, Andreas Nechansky, Wolfgang Jost, Gilbert Gorr
-
Patent number: 9051577Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that • the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and • at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.Type: GrantFiled: July 11, 2007Date of Patent: June 9, 2015Assignee: GREENOVATION BIOTECH GMBHInventors: Manfred Schuster, Ralf Kircheis, Andreas Nechansky, Wolfgang Jost, Gilbert Gorr
-
Publication number: 20150079632Abstract: The invention relates to a method for producing a recombinant protein in cells with a cell wall, comprising the step of increasing the secretion of the recombinant protein through the cell wall by expression of the protein in the cells in a culture medium containing a combination of a surface-active polymer and monovalent metal ions and with an osmolarity at least 0.32 osmol/L, said invention further relating to culture media and nutrient mixtures for the method.Type: ApplicationFiled: April 17, 2013Publication date: March 19, 2015Applicant: GREENOVATION BIOTECH GMBHInventors: Wolfgang Jost, Mathias Knappenberger, Doreen Claussnitzer, Andreas Schaaf
-
Patent number: 8790928Abstract: A method of amplifying gene expression in a moss plant cell or moss tissue, DNA constructs therefor, moss plant cells and uses thereof for the production of protein.Type: GrantFiled: July 29, 2004Date of Patent: July 29, 2014Assignee: Greenovation Biotech GmbHInventor: Gilbert Gorr
-
Patent number: 8323650Abstract: The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.Type: GrantFiled: May 24, 2010Date of Patent: December 4, 2012Assignees: Meridian Biopharmaceuticals GmbH, Greenovation Biotech GmbHInventors: Manfred Schuster, Gottfried Himmler, Guenter Waxenecker, Geert C. Mudde, Manuela Loidl, Gerda Redl, Hans Loibner
-
Publication number: 20110020331Abstract: The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.Type: ApplicationFiled: May 24, 2010Publication date: January 27, 2011Applicants: MERIDIAN BIOPHARMACEUTICALS GmbH, GREENOVATION BIOTECH GmbHInventors: Manfred Schuster, Gottfried Himmler, Günter Waxenecker, Geert C. Mudde, Manuela Loidl, Gerda Redl, Hans Loibner
-
Publication number: 20100310551Abstract: The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen.Type: ApplicationFiled: March 29, 2010Publication date: December 9, 2010Applicants: MERIDIAN BIOPHARMACEUTICALS GmbH, GREENOVATION BIOTECH GmbHInventors: Hans LOIBNER, Günter WAXENECKER, Gottfried HIMMLER, Helmut ECKERT, Manfred SCHUSTER, Ralf KIRCHEIS
-
Patent number: 7834167Abstract: Disclosed are isolated nucleic acid molecules encoding wild type nucleus derived moss expression promoting regions (MEPRs) as well as a method for producing recombinant polypeptides using such MEPRs.Type: GrantFiled: June 6, 2008Date of Patent: November 16, 2010Assignee: Greenovation Biotech GmbHInventors: Marta Rodriguez-Franco, Wolfgang Jost, Andreas Weise, Gilbert Gorr
-
Patent number: 7781197Abstract: Bryophyte plants and bryophyte plant cells comprising dysfunctional fucT and xylT genes and an introduced glycosyltransferase gene, methods for the production of glycosylated proteins therewith, vectors and uses thereof.Type: GrantFiled: December 18, 2003Date of Patent: August 24, 2010Assignee: greenovation Biotech GmbHInventors: Ralf Reski, Gilbert Gorr, Eva Decker, Christian Stemmer, Otmar Lienhart, Anna Koprivova
-
Patent number: 7759464Abstract: The invention relates to a monoclonal antibody, or fragment of the antibody, that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region of the antibody, or fragment of the antibody, carries a bi-sected hybrid type N-glycosylation pattern and that the antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.Type: GrantFiled: July 14, 2004Date of Patent: July 20, 2010Assignees: Greenovation Biotech GmbH, Meridian Biopharmaceuticals GmbHInventors: Manfred Schuster, Gottfried Himmler, Gunter Waxenecker, Geert C. Mudde, Manuela Loidl, Gerda Redl, Hans Loibner
-
Patent number: 7741539Abstract: The present invention relates to a method for producing heterologous glycosylated proteins in non-animal eukaryotic cells such as in transformed bryophyte, yeast, ciliate or algae cells. In particular, the method relates to a method for producing glycosylated proteins comprising animal glycosylation patterns—comprising sialic acid residues—, such as pharmaceutical proteins for use in mammals, e.g. humans, in bryophyte cells such as those of Physcomitrella patens, the genetic material required therefore, such as DNA and RNA, vectors, host cells, methods of introducing genetic material there into, and uses thereof. Furthermore, the present invention relates to novel polypeptides and proteins obtained by the method according to the invention. Moreover, the present invention provides a method of producing sialic acid or CMP-sialic acid in a transformed non-mammalian eukaryotic cell, tissue or organism.Type: GrantFiled: July 12, 2006Date of Patent: June 22, 2010Assignee: greenovation Biotech GmbHInventors: Gilbert Gorr, Heike Launhardt, Marta Rodriguez Franco, Christian Stemmer
-
Publication number: 20100050292Abstract: The invention discloses DNA molecules encoding galactosyltransferases, recombinant host cells, tissues or organisms comprising dysfunctional galactosyltransferase gene(s), recombinant host cells, tissues or organisms comprising an introduced functional galactosyltransferase gene, methods for the production of proteins therewith, methods for the production of galactosyltransferase and vectors and uses thereof.Type: ApplicationFiled: September 28, 2007Publication date: February 25, 2010Applicant: GREENOVATION BIOTECH GMBHInventors: Heike Launhardt, Christian Stemmer, Wolfgang Jost, Gilbert Gorr, Ralf Reski, Stefan Rensing